The Global PET-CT Scanner Device Market was valued at US$ 1.9 billion in 2017, and is projected to exhibit a CAGR of 5.1% over the forecast period (2018 - 2026)
The decreasing cost of PET-CT scanners, rising cancer incidence, and increasing clinical applications of these devices are likely to fuel the growth of the PET-CT scanner device market throughout the forecast period. Cancer incidence rates in children and adolescents have grown by 0.6 percent per year since 1975, according to the American Cancer Society. Cancer is the second leading cause of mortality among children aged 1 to 14 years in the United States, trailing only accidents. An projected 10,590 children of this age range will be diagnosed with cancer in 2018.
Furthermore, ongoing research into new radiotracers is projected to stimulate demand for PET-CT scanners device market in clinical applications such as oncology, Alzheimer's disease, and others. These devices' technological breakthroughs include the addition of characteristics such as high picture contrast and resolution, the removal of metal artefacts, better big field-of-view imaging, and others. Toshiba Medical introduced the Celesteion PUREViSION Edition PET-CT system in 2017 to aid in the diagnosis and treatment of oncology patients. It has a real field-of-view of 70 cm and SUREFLiGHT reconstruction technology, which includes Time of Flight and Point Spread Function approaches, and provides high contrast and clear images to oncologists.
The PET-CT has several advantages, including better activity localization to normal versus abnormal structures, better identification of inflammatory lesions, overall reduced scan time, discovery of serendipitous abnormalities, CT visualisation of PET-negative lesions, confirmation of abnormal or unusual sites, and improved localization for radiotherapy or biopsy. Characterization and localisation of lesions to confirm or rule out malignancy is a critical function of these devices.
No comments:
Post a Comment